Intrust Bank NA Reduces Position in Edwards Lifesciences Co. (NYSE:EW)

Intrust Bank NA decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 14.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,582 shares of the medical research company’s stock after selling 1,741 shares during the period. Intrust Bank NA’s holdings in Edwards Lifesciences were worth $783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Townsquare Capital LLC boosted its position in Edwards Lifesciences by 20.5% in the third quarter. Townsquare Capital LLC now owns 5,208 shares of the medical research company’s stock valued at $344,000 after buying an additional 886 shares during the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of Edwards Lifesciences by 12.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 26,167 shares of the medical research company’s stock valued at $1,727,000 after acquiring an additional 2,900 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec increased its stake in shares of Edwards Lifesciences by 56.7% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 82,974 shares of the medical research company’s stock worth $5,475,000 after acquiring an additional 30,038 shares during the period. Edgestream Partners L.P. raised its holdings in shares of Edwards Lifesciences by 117.1% during the third quarter. Edgestream Partners L.P. now owns 10,294 shares of the medical research company’s stock worth $679,000 after purchasing an additional 5,552 shares during the last quarter. Finally, Maverick Capital Ltd. acquired a new stake in Edwards Lifesciences during the 3rd quarter worth about $1,953,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.4 %

NYSE:EW opened at $70.90 on Friday. The stock has a fifty day moving average price of $71.49 and a 200 day moving average price of $70.52. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.73. The firm has a market cap of $41.68 billion, a PE ratio of 10.17, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the transaction, the chief financial officer now owns 30,387 shares of the company’s stock, valued at $2,153,526.69. The trade was a 27.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,553 shares of company stock worth $4,513,064. 1.29% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of several analyst reports. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Barclays lifted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Finally, Morgan Stanley increased their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.